Lexaria says DehydraTECH 3.0 retatrutide tablet boosts absorption up to 4,552% in dog study
LEXX•Dog-study pharmacokinetic results for DehydraTECH 3.0
Lexaria reported dog-study PK results showing higher oral absorption for amycretin and retatrutide using its DehydraTECH 3.0 formulations.
- Best amycretin DHT3.0 tablet delivered 1.65% absolute bioavailability, up 481.14% versus the DHT2.0 reference tablet.
- The same amycretin result more than doubled a 0.7% absolute bioavailability level reported in a separate Novo Nordisk primate study.
- Best retatrutide DHT3.0 tablet raised absorption 4,552.2% versus the DHT2.0 reference tablet; absolute bioavailability reached 0.1%.
- Top retatrutide DHT3.0 capsules reached 0.26% absolute bioavailability, supporting partnering outreach for oral next-generation GLP-1 drugs.
